PIK3CA and head and neck squamous cell carcinoma: In addition to trastuzumab, nearly identical findings were reported in HNSCC [92], in which hotspot mutations in PIK3CA and RAS can predict resistance to cetuximab, a monoclonal antibody targeting epidermal growth factor receptor (EGFR).